Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma

被引:143
作者
Nagler, A
Slavin, S
Varadi, G
Naparstek, E
Samuel, S
Or, R
机构
[1] Hadassah Univ Hosp, Dept Bone Marrow Transplant, IL-91120 Jerusalem, Israel
[2] Hadassah Univ Hosp, Canc Immunotherapy & Immunobiol Res Ctr, IL-91120 Jerusalem, Israel
关键词
allogeneic; peripheral blood stem cell transplantation; malignant lymphoma; fludarabine; low intensity conditioning regimen;
D O I
10.1038/sj.bmt.1702392
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Relapse is a serious complication following high-dose therapy and autologous bone marrow transplantation (ABMT) for malignant lymphoma (ML), Allogeneic transplantation (alloSCT) is a therapeutic option. However, it is associated with a high incidence of transplant-related organ toxicity and mortality. We recently reported fast engraftment and minimal transplant-related toxicity, using fludarabine-based conditioning with reduced amounts of chemotoxic drugs prior to alloSCT, We now present our experience with 23 heavily treated high risk ML patients who underwent matched alloSCT following the same low intensity conditioning. The patients (20 male, three female) were aged 13-63 years, Nineteen had NHL and four HD (resistant disease 12, partial remission 11), Five were post ABMT, Twenty-two patients had fully matched sibling donors, and one a fully matched unrelated donor. Engraftment was fast. There was no rejection or non-engraftment, Organ toxicity was moderate with no liver or renal toxicity >grade II, Four patients developed >grade II graft-versus-host disease (GVHD). Seven patients died - four of grade III-IV GVHD and severe infections, two of bacterial sepsis, one of pulmonary failure. Ten patients are alive after 22.5 (15-37) months, Survival and disease-free survival at 37 months are both 40%, Probability of relapse is 26%, These encouraging results suggest that alloSCT following fludarabine-based low intensity conditioning in high-risk patients merits further evaluation.
引用
收藏
页码:1021 / 1028
页数:8
相关论文
共 60 条
[21]   IMMUNOSUPPRESSION WITH PURINE ANALOGS - THE FLIP SIDE OF THE GOLD COIN [J].
KEATING, MJ .
ANNALS OF ONCOLOGY, 1993, 4 (05) :347-348
[22]  
KEATING MJ, 1993, SEMIN ONCOL, V20, P1
[23]   DOSE INTENSIFICATION WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN RELAPSED AND RESISTANT HODGKINS-DISEASE - RESULTS OF A BNLI RANDOMIZED TRIAL [J].
LINCH, DC ;
WINFIELD, D ;
GOLDSTONE, AH ;
MOIR, D ;
HANCOCK, B ;
MCMILLAN, A ;
CHOPRA, R ;
MILLIGAN, D ;
HUDSON, GV .
LANCET, 1993, 341 (8852) :1051-1054
[24]  
Mandigers CMPW, 1998, BRIT J HAEMATOL, V100, P198
[25]  
McSweeney PA, 1998, BLOOD, V92, p519A
[26]   Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease [J].
Milpied, N ;
Fielding, AK ;
Pearce, RM ;
Ernst, P ;
Goldstone, AH .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) :1291-1296
[27]   Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation [J].
Nagler, A ;
Ackerstein, A ;
Or, R ;
Naparstek, E ;
Slavin, S .
BLOOD, 1997, 89 (11) :3951-3959
[28]   VARIABLE NUMBER OF TANDEM REPEAT (VNTR) MARKERS FOR HUMAN-GENE MAPPING [J].
NAKAMURA, Y ;
LEPPERT, M ;
OCONNELL, P ;
WOLFF, R ;
HOLM, T ;
CULVER, M ;
MARTIN, C ;
FUJIMOTO, E ;
HOFF, M ;
KUMLIN, E ;
WHITE, R .
SCIENCE, 1987, 235 (4796) :1616-1622
[29]   Potential and distribution of transplanted hematopoietic stem cells in a nonablated mouse model [J].
Nilsson, SK ;
Dooner, MS ;
Tiarks, CY ;
Weier, HU ;
Quesenberry, PJ .
BLOOD, 1997, 89 (11) :4013-4020
[30]   Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation [J].
Or, R ;
Ackerstein, A ;
Nagler, A ;
Amar, A ;
Naparstek, E ;
Varadi, G ;
Kapelushnik, J ;
Samuel, S ;
Pugatsch, T ;
Brautbar, C ;
Slavin, S .
JOURNAL OF IMMUNOTHERAPY, 1998, 21 (06) :447-453